| Protein Name: | Receptor tyrosine-protein kinase erbB-2 (P04626) |
|---|---|
| Gene Name: | ERBB2 |
| Description: | Receptor tyrosine-protein kinase erbB-2 precursor (EC 2 7 10 1) (p185erbB2) (C-erbB-2) (NEU proto-oncogene) (Tyrosine kinase-type cell surface receptor HER2) (MLN 19) |
| PDB ID: | 1MFG |
| Protein Family: | |
| Protein Category: | Enzyme |
This panel provides drug-protein interaction and their ADRs along with references
| Interacting Drugs | Toxicity | Mechanism | Reference |
|---|---|---|---|
| Anthracyclines | Cardiac Dysfunction | C-erbB-2 (HER2/neu) protein overexpression or amplification has been noted in some solid tumors a molecular target for tumor suppression,combination therapy which suggests that anthracyclines increases the incidence and severity of cardiac dysfunction [ ADR Type 2 ] | Clinical implications of trastuzumab |
| Anthracyclines | Toxicities Of Infusion Reaction | C-erbB-2 (HER2/neu) protein overexpression or amplification has been noted in some solid tumors a molecular target for tumor suppression,combination therapy which suggests that anthracyclines lead to toxicities of infusion reaction [ ADR Type 2 ] | Clinical implications of trastuzumab |
| Trastuzumab | Tumor Suppression | C-erbB-2 (HER2/neu) protein overexpression or amplification has been noted in some solid tumors a molecular target for tumor suppression [ ADR Type 2 ] | Clinical implications of trastuzumab |
This panel provides information on drug category
| Toxicity | Source |
|---|